Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
169.44B
Market cap169.44B
Price-Earnings ratio
9.45
Price-Earnings ratio9.45
Dividend yield
3.18%
Dividend yield3.18%
Average volume
17.76M
Average volume17.76M
High today
$38.49
High today$38.49
Low today
$38.05
Low today$38.05
Open price
$38.21
Open price$38.21
Volume
9.40M
Volume9.40M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

Zacks 3h
Novo Nordisk Dips More Than Broader Market: What You Should Know

Novo Nordisk (NVO Quick QuoteNVO - Free Report) closed at $38.31 in the latest trading session, marking a -1.03% move from the prior day. The stock traile...

Novo Nordisk Dips More Than Broader Market: What You Should Know
Benzinga 7h
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide

Novo Nordisk A/S (NYSE:NVO) announced on Tuesday new real-world evidence demonstrating that escalating semaglutide dosage reduces major adverse cardiovascular e...

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide
TipRanks 13h
Novo Nordisk enters into license agreement with Hengrui Pharma on HRS-1596

The company stated: “Novo Nordisk (NVO) announced that it has entered into a license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like p...

More NVO News

TipRanks 14h
Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

Novo Nordisk (NVO) announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the an...

MarketWatch 14h
Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy. Novo Nordisk...

Novo Nordisk strikes second licensing deal since frosty capital-markets day
Seeking Alpha 18h
Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui

Jiangsu Hengrui Pharmaceuticals has agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk (NVO) in a deal worth up to $2.6B....

Novo Nordisk strikes $2.6B obesity drug deal with China's Hengrui
The Wall Street Journal 19h
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma

Novo Nordisk will pay Hengrui $300 million upfront, with the rest of the potential deal value tied to milestones. Andrew Silver / Reuters Novo Nordisk NOVO.B -...

Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
TipRanks 1d
Option traders moderately bearish in Novo Nordisk with shares down 0.22%

Option traders moderately bearish in Novo Nordisk (NVO), with shares down 8c near $38.72. Options volume roughly in line with average with 78k contracts traded...

TipRanks 1d
Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme

Novo Nordisk ( (NVO) ) has shared an announcement. On 28 September 2026, Novo Nordisk reported progress on its ongoing share repurchase programme, part of a br...

MarketWatch 1d
Taking Ozempic? A routine eye exam could help you understand your risk for vision loss.

A routine eye exam could help the millions of Americans taking GLP-1s better understand if they are at risk for a rare form of vision loss. As part of a routin...

Taking Ozempic? A routine eye exam could help you understand your risk for vision loss.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.